High-grade squamous intraepithelial lesions (HSIL)

Clinical trials for High-grade squamous intraepithelial lesions (HSIL) explained in plain language.

Never miss a new study

Get alerted when new High-grade squamous intraepithelial lesions (HSIL) trials appear

Sign up with your email to follow new studies for High-grade squamous intraepithelial lesions (HSIL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

CRISPR zaps HPV in cervical lesions: first human test begins

Disease control Stopped early

This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up…

Matched conditions: HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL)

Early phase 1 • Sponsor: Shanghai BDgene Co., Ltd. • Aim: Disease control

Last updated Sep 06, 2026 00:00 UTC

High-grade squamous intraepithelial lesions (HSIL)

Get alerted when new High-grade squamous intraepithelial lesions (HSIL) trials appear

CRISPR zaps HPV in cervical lesions: first human test begins